๐ฐ Kumar Budur News
Page 3 - Kumar Budur News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kumar Budur. Real-time updates on events, politics, business and more.
October 11, 2023
The Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia.ย
October 6, 2023
Harmony announced new data from its phase 2 study evaluating pitolisant for excessive daytime sleepiness in Prader-Willi syndrome.
October 5, 2023
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
September 12, 2023
The FDA has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia.
September 8, 2023
The FDA has granted Harmony Biosciences Orphan Drug Designation for pitolisant for the treatment of idiopathic hypersomnia.
September 7, 2023
PLYMOUTH MEETING, Pa., Sept. 7, 2023 /PRNewswire/ --ย Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients...
September 7, 2023
Shares of Harmony Biosciences Holdings, Inc. (HRMY) are up 4% on Thursday after the company's Pitolisant Tablets was granted FDA Orphan Drug designation for the treatment of idiopathic hypersomnia (IH), a rare and chronic neurological disease that is characterized by excessive daytime sleepiness.
September 7, 2023
The FDA has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia.
August 3, 2023
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2023 Earnings Call Transcript August 1, 2023 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.57 EPS, expectations were $0.63. Operator: Good morning. My name is Todd, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony […]
August 1, 2023
HRMY earnings call for the period ending June 30, 2023.